Active	Status	Sponsor type	Region	Phase	Filter
2 Active 0 Inactive 2 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

2 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Müller, Volker
ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC	Active, not recruiting	3	1684	Europe	Ribociclib 200Mg Oral Tablet, Kisqali	West German Study Group, Novartis, Genomic Health®, Inc.	Breast Cancer Female	07/27	07/27
NCT03809962: Efficacy and Safety of Ostenil® Plus in the Treatment of Coxarthrosis	Active, not recruiting	N/A	250	Europe	Ostenil® Plus	TRB Chemedica AG	Coxarthrosis	02/25	02/25